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Background. Diagnosis of extrapulmonary tuberculosis (TB) remains challenging. We sought to determine the prevalence of 
disseminated TB by testing urine with TB-lipoarabinomannan (TB-LAM) lateral flow assay and Xpert MTB/RIF Ultra (Ultra) in 
hospitalized adults.
Methods. We prospectively enrolled human immunodeficiency virus (HIV)-positive adults with suspected meningitis 
in Uganda during 2018–2020. Participants underwent standardized urine-based TB screening. Urine (60 mcL) was tested with 
TB-LAM (Alere), and remaining urine was centrifuged with the cell pellet resuspended in 2 mL of urine for Xpert Ultra testing.
Results. We enrolled 348 HIV-positive inpatients with median CD4 of 37 cells/mcL (interquartile range, 13–102 cells/mcL). 
Overall, 26% (90 of 348; 95% confidence interval [CI], 21%–30%) had evidence of disseminated TB by either urine assay. Of 243 par-
ticipants with both urine TB-LAM and Ultra results, 20% (48 of 243) were TB-LAM-positive, 12% (29 of 243) were Ultra-positive, 
and 6% (14 of 243) were positive by both assays. In definite and probable TB meningitis, 37% (14 of 38) were TB-LAM-positive and 
41% (15 of 37) were Ultra-positive. In cryptococcal meningitis, 22% (40 of 183) were TB-LAM-positive and 4.4% (6 of 135) were 
Ultra-positive. Mortality trended higher in those with evidence of disseminated TB by either assay (odds ratio = 1.44; 95% CI, 
0.83–2.49; P = .19) and was 6-fold higher in those with definite TB meningitis who were urine Ultra-positive (odds ratio = 5.67; 95% 
CI, 1.13–28.5; P = .04).
Conclusions. In hospitalized Ugandans with advanced HIV disease and suspected meningitis, systematic screening with urine 
TB-LAM and Ultra found a high prevalence of urine TB test positivity (26%). In those with TB meningitis, urine tests were positive 
in over one third. There was little concordance between Ultra and TB-LAM, which warrants further investigation.
Keywords.  HIV; meningitis; TB-LAM; tuberculosis; Xpert MTB/RIF Ultra.
Tuberculosis (TB) is a major cause of death in people with 
human immunodeficiency virus (HIV). Human immuno-
deficiency virus-associated TB is often disseminated, de-
fined as having 2 or more noncontiguous sites resulting from 
lymphohematogenous dissemination of Mycobacterium tuber-
culosis [1, 2]. Postmortem studies have shown that >90% of 
cases involve multiple organ systems including spleen, liver, 
multiple lymph node groups, kidneys, or central nervous 
system [3]. Diagnosis of disseminated TB is taxing due to chal-
lenges in accessing clinical samples from the affected sites. In 
addition, in the context of HIV-associated meningitis, of which 
cryptococcal meningitis is the most common cause [4, 5], dis-
seminated TB may not be considered due to the considerable 
overlap in the clinical presentation of the 2 diseases: ie, fevers, 
night sweats, cough, and wasting. There are case reports and 
case series of cryptococcal meningitis coinfection with TB 
[6, 7], including TB meningitis [8], but no published studies 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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systematically screened for TB among HIV-positive adults pre-
senting with neurological infections. It is unknown to what 
extent undiagnosed disseminated TB infection contributes to 
the high mortality in HIV-infected patients with neurological 
infections.
Urine-based TB diagnostics have the potential to re-
duce missed TB diagnoses and reduce mortality in pa-
tients with advanced HIV disease. Urine is easily obtainable 
and can be tested using either a lateral flow assay (LFA) for 
TB-lipoarabinomannan (TB-LAM) or the Xpert MTB/RIF 
assay (Xpert; Cepheid, Sunnyvale, CA). Tuberculosis-LAM 
is emerging as the key urine-based TB diagnostic. Published 
data, including a 2016 Cochrane review, demonstrate that the 
first-generation Alere Determine TB-LAM Ag assay (TB-LAM; 
Alere, Waltham, MA) has a sensitivity of 40%–70% and a 
specificity of ≥98% in TB/HIV-coinfected patients with CD4 
counts <100 cells/μL [9–11]. The STAMP trial evaluated the use 
of the Alere Determine TB-LAM Ag assay and Xpert MTB/RIF 
among HIV-positive patients hospitalized in Malawi and South 
Africa [12] and demonstrated reduced all-cause 56-day mor-
tality with urine-based TB-LAM screening in certain high-risk 
subgroups of those with CD4 T-cell counts <100 cells/μL, se-
vere anemia (hemoglobin <8 g/dL), or clinically suspected TB. 
These findings corroborate those of an earlier study that found a 
4% (95% confidence interval [CI], 1%–7%) reduction in 8-week 
all-cause mortality in hospitalized HIV-positive adults with 
urine TB-LAM screening [13]. STAMP found that TB-LAM 
provided a 2-fold higher diagnostic yield than urine Xpert 
MTB/RIF. As a result, the World Health Organization (WHO) 
has recently updated their guidelines to support the expanded 
use of the Alere TB-LAM assay in all patients hospitalized with 
symptoms and signs of TB, CD4 count <200 cells/μL (irrespec-
tive of symptoms), or clinically advanced HIV disease, or who 
are seriously ill [14] .
Due to the limited sensitivity of urine Xpert MTB/RIF, urine 
screening with Xpert is not currently recommended by the 
WHO. In 2017, however, Cepheid introduced the re-engineered 
Xpert MTB/RIF Ultra (Ultra) with technical enhancements re-
sulting in 7-fold improved analytical sensitivity and addition of 
a “trace” category for the lowest bacillary load [15]. Two diag-
nostic accuracy studies of Ultra on cerebrospinal fluid (CSF) 
in HIV-positive Ugandan adults with suspected TB meningitis 
found Ultra to be significantly more sensitive than Xpert MTB/
RIF against a composite reference standard [16, 17]. However, 
publications on Xpert Ultra use in urine have thus far been lim-
ited, and include a case report [18] and a small number of sam-
ples in diagnostic accuracy studies of Ultra in extrapulmonary 
samples [19, 20], without evaluation as a screening tool. In 
a Ugandan study, the performance of urine Xpert Ultra in 
diagnosing pulmonary TB was assessed, and researchers 
found that Xpert Ultra had significantly higher sensitivity than 
TB-LAM, with 50% sensitivity in patients with CD4 <100 cells/
µL [21]. This study, which also included HIV-negative patients, 
used sputum-based diagnostics as the reference standard. The 
suboptimal sensitivity of urine diagnostics in pulmonary TB di-
agnosis is perhaps not surprising because sputum studies are 
often discordant with urine diagnostics if the TB has not dis-
seminated beyond the lungs, as may often be the case in HIV-
negative patients [22]. In our study, we sought to determine the 
prevalence of disseminated TB infection by testing urine with 
the Alere TB-LAM LFA and Xpert Ultra in HIV-positive adults 
presenting with suspected meningitis.
METHODS
Study Population
We conducted a prospective cohort study as part of screening 
for an observational meningitis diagnostic study and a TB 
meningitis randomized controlled trial (RifT trial: ISRCTN 
15668391). Consecutive HIV-infected adults presenting with 
suspected meningitis to Mulago National Referral Hospital, 
Kampala or Mbarara Regional Referral Hospital were screened 
for infectious meningitis etiologies using a stepwise diag-
nostic algorithm, as described elsewhere [23], after provision 
of written informed consent. Inclusion criteria for diagnostic 
testing were HIV-positive adults (≥18  years) presenting with 
suspected meningitis (eg, headache or altered mental status, 
clinical signs of meningism). From March 27, 2018 to February 
6, 2020, urine-based screening for TB was conducted using an 
Alere Determine TB-LAM LFA assay (TB-LAM; Alere) and 
Xpert Ultra (Cepheid). Urine TB testing was conducted for all 
patients within 48 hours of admission to hospital. Tuberculosis 
screening was performed irrespective of TB symptoms, past or 
current TB therapy, or CD4 T-cell count among consented par-
ticipants. Cryptococcal meningitis was diagnosed by positive 
CSF cryptococcal antigen (CrAg) LFA at the bedside and later 
confirmed by culture. Participants with suspected or confirmed 
TB meningitis were categorized according to the 2010 uni-
form case definition; with “definite TB meningitis” comprising 
those with microbiologically confirmed M tuberculosis in CSF 
and “probable TB meningitis” comprising those who score ≥10 
points (or ≥12 points if brain imaging is performed) on clinical, 
CSF, and imaging criteria but who are negative for TB on CSF 
testing [24]. Due to its low specificity in a high HIV-burden set-
ting “possible TB meningitis” was not included as a discrete di-
agnostic category.
Study Procedures
A suggested minimum of 30 mL of midstream, early morning 
urine was collected from participants able to provide a sample. 
In the laboratory, 60  μL of unconcentrated urine was tested 
with the TB-LAM according to the manufacturers’ instructions, 
and test samples were classified according to the reference card 
with grade 1 or above considered positive according to the 
WHO guidelines [14]. The remainder of the urine specimen 
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was measured using calibrated Falcon tubes, the volume was re-
corded, and the urine was processed for Ultra testing. The urine 
was concentrated by centrifugation at 3000 ×g for 15 minutes at 
room temperature. Surplus urine was decanted off leaving 2 mL 
in which the cell pellet was resuspended and loaded into the car-
tridge for Xpert Ultra testing. No buffer was used. Tuberculosis-
LAM and Xpert Ultra testing were performed simultaneously 
by a laboratory technologist blinded to the patient history, and 
the TB-LAM result was reported independently without aware-
ness of the Ultra result. Both results were reported in real-time 
to the clinical team.
Clinical management, including timing of commencement 
of anti-TB therapy and additional TB investigation, was at 
the discretion of the attending physician; wherever possible, 
anti-TB therapy was started as soon as possible for all patients 
with a positive TB-LAM and/or Xpert Ultra result, and addi-
tional work-up, including collection of additional clinical sam-
ples where possible for TB microbiology (Xpert Ultra and/or 
Mycobacteria Growth Inhibitor Tube [MGIT] culture; Becton 
Dickinson, Franklin Lakes, NJ), chest radiography, and abdom-
inal ultrasound, was performed where indicated and feasible.
Baseline demographics, clinical characteristics including an-
tiretroviral therapy (ART) use, and laboratory data were col-
lected as part of the screening process. Consented participants 
were followed up until hospital discharge or through >10 weeks 
if enrolled into a meningitis clinical trial.
Ethics
All participants (or a surrogate in cases of mental incapacity) pro-
vided written informed consent for urine testing, lumbar punc-
ture, CSF testing, CSF storage, and data collection. Approval for 
the studies was obtained from the Mulago Hospital Research 
Ethics Committee (MHREC1260 and MHREC1246), Uganda 
National Council for Science and Technology, University of 
Minnesota, and the London School of Hygiene and Tropical 
Medicine.
Statistical Analysis
Statistical analysis is primarily descriptive with the primary 
endpoint of interest being the prevalence of disseminated TB 
detected by urine testing. We compared baseline character-
istics across meningitis etiologies, with Kruskall-Wallis tests 
comparing continuous variables and χ 2 tests comparing catego-
rical variables. We compared the proportion of positive Urine 
TB-LAM results and the distribution of TB-LAM grade across 
meningitis etiologies using a χ 2 test. We compared congruency 
in positive TB-LAM versus Xpert Ultra tests by McNemar’s 
test, and we compared the distribution of urine Xpert Ultra 
semiquantitative grade across meningitis etiologies using a 
χ 2 test and Fisher’s exact test (as appropriate according to 
sample size). We tested the relationship between urine volume 
and a positive Xpert Ultra result using a χ 2 test with volume 
dichotomized at the median 24 mL (range, 4.5–45 mL). We re-
ported the proportion surviving hospitalization by each urine 
TB diagnostics result, and we compared test results and mor-
tality using univariable logistic regression. P values were not 
adjusted for multiple testing. All analyses were conducted using 
SAS (version 9.4; SAS Institute, Cary, NC).
RESULTS
Patient Demographics
We enrolled 348 HIV-positive hospitalized participants, 58% 
(201 of 348) of whom were men. The median age was 35 years 
(interquartile range [IQR], 29–42). The study participants had 
advanced HIV disease (median CD4 = 37 cells/μL; IQR, 13–102 
cells/mcL), despite 48% (167 of 347) reporting ART use at the 
time of presentation (implying virologic failure, suboptimal ad-
herence, or recent initiation). The majority of participants had 
cryptococcal meningitis (57%, 198 of 348); 18% (62 of 348) had 
definite or probable TB meningitis according to the uniform 
clinical case definition [24]. Cerebrospinal fluid features by 
meningitis etiology are shown in Table 1.
Diagnostic Yield of Urine Tuberculosis-Lipoarabinomannan and Ultra
Overall, 26% (90 of 348; 95% CI, 21%−30%) of the study parti-
cipants had evidence of disseminated TB by positive TB urine 
assay: 23% (75 of 327; 95% CI, 18%−27%) positive by urine 
TB-LAM, and 11% (29 of 264; 95% CI, 7%−15%) positive by 
urine Xpert Ultra. In cryptococcal patients, 22% (40 of 183) had 
evidence of disseminated TB by urine TB-LAM and 4.4% (6 of 
135) by urine Xpert Ultra. In definite TB meningitis patients, 
37% (14 of 38) had a positive urine TB-LAM and 41% (15 of 
37) had a positive urine Xpert Ultra. In probable TB meningitis 
patients, 41% (9 of 22) had a positive urine TB-LAM and 21% (4 
of 19) had a positive on urine Xpert Ultra. In a composite of def-
inite and probable TB meningitis, 37% (23 of 62) had a positive 
urine TB-LAM and 34% (19 of 56) had a positive Xpert Ultra 
(Table 2 and Supplemental Figure 1). Among urine TB-LAM-
negative subjects, the number needed to test with Xpert Ultra to 
diagnose an additional case of disseminated TB was 13 persons 
(95% CI, 8.0−22.9).
Concordance Between Tuberculosis-Lipoarabinomannan and Ultra
Overall, 243 participants had both urine TB-LAM and Xpert 
Ultra results available for paired analysis. Of 63 participants 
with a positive urine TB assay, 76% (48 of 63)  were positive 
by TB-LAM and 46% (29 of 63) were positive by Xpert Ultra 
(P = .01). Only 22% (14 of 63) of those with a positive urine TB 
test were positive by both TB-LAM and Ultra (Figure 1). The 
overlap of TB-LAM and Ultra was greater among those with 
definite TB meningitis. Of the 35 definite TB meningitis partici-
pants tested with both assays, 51% (18 of 35) had positive urine 
test, 34% (12 of 35) were urine TB-LAM positive, and 43% (15 
of 35) were urine Ultra positive with an overlap of 50% (9 of 
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Table 2. Urine TB Diagnostic Test Results by Disease Category
Urine TB Testing Details Cryptococcal Meningitis TBM (Confirmed) TBM (Probable) Unknown Othera P Valueb
N 198 40 22 88  
Urine TB-LAM      
Tested with TB-LAM, N 183 38 22 84  
Urine TB-LAM positive, n (%) 40 (21.9%) 14 (36.8%) 9 (40.9%) 12 (14.3%) <.01
 LAM Grade 1 25 (13.7%) 5 (13.2%) 4 (18.2%) 7 (8.3%)  
 LAM Grade 2 9 (4.9%) 0 (0.0%) 4 (18.2%) 4 (4.8%)  
 LAM Grade 3 5 (2.7%) 7 (18.4%) 1 (4.5%) 0 (0.0%)  
 LAM Grade 4 1 (0.5%) 2 (5.3%) 0 (0.0%) 1 (1.2%)  
Urine Xpert Ultra      
Tested with Xpert Ultra, N 135 37 19 73  
Urine Xpert Ultra positive, n (%) 6 (4.4%) 15 (40.5%) 4 (21.1%) 4 (5.5%) <.001
 Semiquantitative trace 1 (0.7%) 4 (10.8%) 1 (5.3%) 0 (0.0%)  
 Semiquantitative very low 1 (0.7%) 4 (10.8%) 0 (0.0%) 1 (1.4%)  
  Semiquantitative low 2 (1.5%) 4 (10.8%) 3 (15.8%) 0 (0.0%)  
 Semiquantitative medium 0 (0.0%) 2 (5.4%) 0 (0.0%) 1 (1.4%)  
  Grade unknown 2 (1.5%) 1 (2.7%) 0 (0.0%) 2 (2.7%)  
Either TB Test Positive      
TB-LAM and/or Xpert Ultra positive 44 (22%) 20 (50%) 11 (50%) 15 (17%) <.001
Abbreviations: TB, tuberculosis; TB-LAM, TB-lipoarabinomannan; TBM, tuberculous meningitis. 
aIncludes possible and nontuberculous meningitis diagnoses.
bP value assessed by χ 2 distribution of LAM positivity and Ultra positivity across disease groups.
Table 1. Participant Baseline Demographics, Clinical, and CSF Findings by Disease Category
Characteristics Cryptococcal Meningitis TBM (Confirmed) TBM (Probable) Unknown Othera
N 198 40 22 88
Age, years 35 [29–42] 32 [28–36] 38 [30–48] 37 [30–44]
Women 79 (40%) 17 (43%) 11 (50%) 40 (45%)
HIV Factors     
CD4+ T cells/μL 23 [8–70] 72 [41–111] 55 [22–186] 205 [45–340]
Currently on ART 91 (46%) 17 (43%) 8 (38%) 51 (58%)
Months on ARTb 2.3 [0.6–29.4] 2.2 [0.7–27.9] 1.5 [0.5–11.3] 6.9 [1.6–73.9]
Clinical     
Fever 77 (52%) 34 (97%) 20 (91%) 46 (68%)
Headache 190 (98%) 34 (94%) 15 (68%) 61 (76%)
Duration of headache 14 [7–21] 14 [8–21] 14 [7–21] 14 [7–30]
Focal neurologic deficit 7 (4%) 15 (38%) 8 (36%) 21 (24%)
Wasting 81 (42%) 23 (58%) 13 (59%) 35 (41%)
Glasgow come score <15 70 (35%) 36 (92%) 19 (86%) 45 (52%)
Seizure 41 (30%) 11 (38%) 4 (21%) 23 (38%)
Weight, kg 52 [45–60] 55 [45–58] 53 [50–60] 50 [50–59]
Cough 56 (39%) 25 (74%) 10 (53%) 39 (61%)
Night sweatsc 31 (25%) 22 (85%) 13 (72%) 24 (44%)
Baseline CSF Results     
Opening pressure, cm H2O 23 [14–32] 19 [10–29] 15 [10–24] 18 [12–23]
Opening pressure <20 cm H2O 66 (38%) 16 (52%) 10 (67%) 40 (62%)
Total WBC count cells μL <5 [<5–50] 30 [<5–220] <5 [<5–200] <5 [<5–30]
Total WBC count <5 μL 117 (60%) 17 (45%) 11 (52%) 61 (71%)
CSF protein, mg/dL 69 [36–100] 128 [61–200] 88 [31–151] 68 [28–111]
CSF WBC <5 μL and protein <45 mg/dL 51 (28%) 5 (15%) 4 (20%) 26 (36%)
Abbreviations: ART, antiretroviral therapy; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; IQR, interquartile range; TBM, tuberculous meningitis; WBC, white blood cells. 
NOTE: Data are n (%) or median [IQR].
aIncludes possible and nontuberculous meningitis diagnoses.
bAmong those on ART at diagnosis.
cData on night sweats were only available for 122 of cryptococcosis, 26 definite TB meningitis, 18 probable TB meningitis, and 54 other.
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18 of positive tests). Overall, 17 persons with microbiologically 
confirmed TB meningitis had negative urinary tests (Figure 2).
Urine Diagnostics as a Predictor of In-Hospital Mortality
Among those who are known to have died in hospital, the me-
dian time to death was 7 days (IQR, 3–12 days). Among parti-
cipants with disseminated TB with either urine assay positive, 
the mortality was 33% (27 of 82), compared with 25% (59 of 
232) among those with negative urine assays (odds ratio = 1.44; 
95% CI, 0.83–2.49; P = .19). The mortality was also higher (al-
beit nonsignificantly) among participants with positive urine 
TB-LAM (32% positive LAM vs 26% negative LAM, P = .32) 
and among urine Xpert Ultra positive participants (36% vs 24%, 
P = .18). However, among those with definite TB meningitis, 
there was 50% mortality (7 of 14) in those with positive urine 
Xpert Ultra compared with 23% (3 of 20)  in those with neg-
ative urine Xpert Ultra (odds ratio = 5.67; 95% CI, 1.13–28.5; 
P = .04). With either urine TB-LAM or Ultra positive, the odds 
of dying were 3-fold higher (odds ratio = 3.00; 95% CI, 0.71–
12.7; P = .14) in those with definite TB meningitis (Table 3).
Relationship Between Urine Volume and Ultra Positivity
Among patients with urine volume measured and recorded, 
13% (8 of 64) of patients with <24 mL tested positive by Ultra, 
and 9% (6 of 65)  of patients with ≥24  mL tested positive by 
Ultra (P = .55). The distribution of urine volume among those 
with definite TB meningitis was the same as the rest of the 
study population, thus larger centrifuged volumes did not yield 
a higher prevalence of detecting TB.
We tested for differences in the demographics, clinical, or 
laboratory parameters of patients who were positive by a single 
urine assay or both assays. We explored available laboratory 
parameters by urine test positivity, and there were no significant 
differences in baseline CD4 count, hemoglobin, or creatinine 
level in patients who had discordant results (Supplementary 
Table 1).
DISCUSSION
We have demonstrated that the prevalence of urine TB test 
positivity is 26% amongst HIV-infected patients presenting to 
hospital with suspected meningitis and advanced HIV disease 
in Uganda. The urine TB-LAM assay had more positive results 
(23%) than urine Xpert Ultra (11%), yet Xpert Ultra positivity 
was associated with higher risk of mortality (36% in-hospital 
mortality), particularly in those with TB meningitis (50% 
in-hospital mortality). Uganda has a high TB incidence rate 
(200 of 100 000 population in 2018); our findings may be gen-
eralizable to many other countries in sub-Saharan Africa with 
similar TB incidence rates [25].
Cryptococcosis and TB coinfection (including TB men-
ingitis) has been described in case reports, and in the 
Cryptococcal Optimal ART Timing (COAT) trial where  18% 
(32 of 177) of participants with cryptococcal meningitis were 
treated for concurrent active TB disease during the 46-week 
study period [26]. However, this is the first study in which dis-
seminated TB has been systematically screened for in an HIV-
associated meningitis cohort. Among the 198 cryptococcal 
meningitis patients, one quarter had a positive urine TB test, 
TB-LAM (22%) or Xpert Ultra (4.4%). The true prevalence of 
disseminated TB could be higher than this given that urine TB 
testing may not detect all forms of disseminated TB. Given the 
considerable overlap in symptoms between cryptococcal men-
ingitis and disseminated TB in advanced HIV disease, it is likely 
that without routine screening for TB, some of these diagnoses 
would be missed, and therefore they may contribute to the high 
mortality associated with cryptococcal meningitis. Consistent 
with other studies, in-hospital mortality was high in our cryp-
tococcal meningitis subgroup and trended towards there being 
34 14 15
Xpert Ultra
N = 180 negative
 by both assays
TB-LAM
Figure 1. Venn diagram of overlap between tuberculosis (TB)-positive urinary as-
says. Of 243 persons with both TB-lipoarabinomannan (TB-LAM) and urine Xpert 
Ultra results, 63 were positive by either TB urinary assay, 76% (48 of 63) of whom 
were positive by TB-LAM and 46% (29 of 63) by Xpert Ultra (P = .01). Only 22% (14 
of 63) of those with a positive urine TB test were positive by both TB-LAM and Ultra. 
Among the 195 persons with a negative TB-LAM, 15 (7.7%) were positive by Xpert 
Ultra, with a number needed to test with Ultra to diagnose an additional case of 





CSF Xpert Ultra positive
(Definite TBM)
TB-LAM
Figure 2. Venn diagram illustrating overlap of tuberculosis-lipoarabinomannan 
(TB-LAM) and urine Ultra among those with definite TB meningitis (TBM). Of 35 
persons with definite TBM tested with both assays, a total of 18 (51%) had positive 
urine test, 12 (34%) were urine TB-LAM positive, and 15 (43%) were urine Ultra 
positive with an overlap of 9 of 18 (50%) positive participants being positive by both 
assays. Overall, 49% (17 of 35) with definite TBM, diagnosed by positive CSF Xpert 
Ultra, had negative urinary tests.
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persistent increased mortality in coprevalent disseminated TB 
infection despite clinical teams having real-time access to TB 
urine diagnostic results; however, this study was not designed 
nor powered to determine an impact of coprevalent TB on 
mortality.
We investigated the clinical utility of TB urine diagnostics in 
TB meningitis, a condition that is notoriously challenging to 
diagnose even with molecular CSF diagnostics. Overall, 50% 
(20 of 40; with both urine tests) of definite TB meningitis par-
ticipants had either a positive TB-LAM or urine Xpert Ultra. 
Among probable TB meningitis cases, patients with highly 
suggestive clinical features but in whom rapid CSF diagnostics 
(acid-fast bacilli [AFB] smear and CSF Xpert Ultra) were neg-
ative, 41% were urine TB-LAM positive and 21% urine Ultra 
positive. A lack of sensitive and timely diagnostics has histor-
ically made TB meningitis diagnoses extremely difficult, and 
therefore treatment for probable TB meningitis rests upon the 
presence of symptoms or signs indicative of meningitis, CSF 
features plus suggestive imaging criteria or confirmed evidence 
of extra-neural TB. The uniform case definition agreed by con-
sensus in 2010 does not include the TB-LAM assay as “evidence 
of extra-neural TB” [24], but our data suggest that this may 
be warranted. In this study a positive urine TB test was inter-
preted as evidence of extra-neural TB when assigning points in 
the uniform case definition. Urine TB diagnostics have the po-
tential to improve our classification of TB meningitis cases and 
warrant investigation in a larger study. Although not routinely 
used as part of a TB meningitis diagnostic work-up, urine is an 
easily obtained sample, and TB-LAM and Ultra are relatively 
low cost; therefore, we advocate their use as adjunctive tests in 
the investigation of patients with suspected TB meningitis.
Urine Xpert Ultra has previously been used to diagnose 
disseminated TB in a case report [18] and has been evalu-
ated as a marker of pulmonary TB in a cross-sectional study 
[21], but this is the first time that urine Xpert Ultra has been 
evaluated as a screening test for disseminated TB in a pro-
spective cohort and correlated with survival. Urine Xpert 
Ultra was positive in 11% of our (tested) cohort overall, 
demonstrating that urine is an additional viable clinical 
sample for use with Ultra. It is interesting to note that in pa-
tients with definite TB meningitis, Xpert Ultra and TB-LAM 
were positive in a similar proportion of patients (41% and 
37% respectively), whilst there were considerably more pos-
itive TB-LAM tests than Xpert Ultra tests in patients with 
cryptococcal meningitis  (22% and 4% respectively). Our 
data raise several questions about the MTB antigen load 
required for respective test positivity, the performance of 
urine Xpert Ultra at different degrees of immunosuppres-
sion, the impact of renal TB infection versus TB bacteremia 
on test performance, and the specificity of TB-LAM in pa-
tients with disseminated fungal diseases or other opportun-
istic infections [27].
In our subgroup analysis, in-hospital mortality was 6-fold 
higher  (50% vs 15%; odds ratio = 5.67; 95% CI, 1.13–28.5; P 
= .04) in patients with definite TB meningitis and a positive 
urine Xpert Ultra in comparison to patients with definite TB 
meningitis and a negative urine tests. These data suggest that 
urine Ultra testing may be a useful test to identify TB menin-
gitis patients with at particularly higher risk of death and thus 
requiring more intensive TB therapy or alternative or adjunc-
tive host-directed immunotherapy. Future research is needed to 
explore whether urine Ultra positivity and the increased mor-
tality relates to burden of MTB infection, host factors, or both.
Overall, there was little concordance between urine Xpert 
Ultra and TB-LAM positivity, only 22% of those positive by 
either test were positive by both assays. A similar observation 
was made in the STAMP trial, in which only 23% of patients 
had both urine TB-LAM and urine Xpert MTB/RIF posi-
tivity [12]. The reasons for this are unclear. We observed no 
statistically significant differences in the demographics, clin-
ical, or laboratory parameters of patients who were positive 
by a single urine assay or both assays, although our study was 
not powered to detect a clear association between these vari-
ables and urine assay positivity. We need to further investigate 
the lack of concordance between TB-LAM and urine Xpert 
Ultra and to explore whether this relates to the following: (1) 
Table 3. In-Hospital Mortality by Urine Diagnostic Result and Meningitis Aetiology by Univariate Logistic Regressiona
Study  
Population














Overall 32% (22 of 68) 26% (60 of 229) 1.35 (0.75–2.42) .32 36% (10 of 28) 24% (51 of 214) 1.78 (0.77–4.09) .18 1.44 (0.83–2.49) .19
Cryptococcal 32% (12 of 38) 27% (36 of 133) 1.24 (0.57–2.72) .59 50% (3 of 6) 23% (28 of 121) 3.32 (0.63–17.4) .16 1.41 (0.67–2.96) .37
TBM, definite 38% (5 of 13) 32% (7 of 22) 1.34 (0.32–5.61) .69 50% (7 of 14) 15% (3 of 20) 5.67 (1.13–28.5) .04 3.00 (0.71–12.7) .14
TBM, probable 50% (4 of 8) 38% (5 of 13) 1.60 (0.27–9.49) .60 0% (0 of 4) 50.0% (7 of 14)     
Other/unknown 11.1% (1 of 9) 19.7% (12 of 61) 0.51 (0.06–4.48) .54 0% (0/4) 22% (13/59)   0.34 (0.04–2.84) .32
Abbreviations: CI, confidence interval; TB, tuberculosis; TB-LAM, TB-lipoarabinomannan; TBM, tuberculous meningitis.
aData represent mortality by TB test status. Hospital outcome was unknown for 34 participants (7.5% of cryptococcal, 7.5% TBM definite, 5% TBM probable, 17% unknown/other menin-
gitis). Among those who are known to have died in hospital, the median time to death was 7 days (interquartile range, 3–12 days).
bEither TB assay positive is any positive urine diagnostic (TB-LAM or Ultra or both) versus both assays being negative.
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variation in the M tuberculosis burden required for test pos-
itivity; (2) interpatient differences in the renal parenchymal 
changes associated with renal TB or HIV-related nephropathy; 
or (3) differences in host immunity that may impact on the 
degree of immune complexing of circulating TB-LAM antigen 
and thereby its potential to cross the basement membrane 
[28]. Such a study could include immunological and renal 
parameters (such as proteinuria or urine-protein to creati-
nine ratio) to investigate whether the degree of immunodefi-
ciency or glomerular pathology may contribute towards the 
likelihood of excreting M tuberculosis bacilli or the TB-LAM 
glycolipid—the latter is only 17.5 kDa without immune com-
plexing but 150–1000  kDa when complexed with anti-LAM 
antibodies—into the urine.
One strength of our study is that we studied a large cohort of 
348 adults and this is the first time that urine TB diagnostics have 
been evaluated in a prospective manner among HIV-associated 
meningitis patients. However, we do recognize limitations to 
our study. Due to either suboptimal volume of urine sample 
or due to Ultra test availability, not all patients had TB-LAM 
and Xpert Ultra test results available for analysis. In instances in 
which urine volume was limited, TB-LAM testing was priori-
tized as per WHO guidelines, and overall more TB-LAM tests 
were conducted because bedside TB-LAM tests were consist-
ently more available than Ultra. To ensure a fair comparison of 
the diagnostic performance of TB-LAM and urine Xpert Ultra, 
the concordance and diagnostic yield of each test was only com-
pared in 243 participants who had both test results available. 
Second, due to the high rates of urinary incontinence in this 
critically ill population, not all participants managed to provide 
the suggested >30 mL of urine. Low urine volume may have im-
pacted the sensitivity of Ultra, although we did not detect a dif-
ference in TB test positivity in urine samples above and below 
the median 24-mL volume. Third, our study was exploratory 
and not powered to detect a clear association between TB-LAM 
and/or Xpert Ultra positivity and death. Although there was a 
trend towards worse outcomes in patients with evidence of dis-
seminated TB, our data herein provide estimates necessary for 
future sample size calculations. Finally, due to the study setting 
and population (critically ill meningitis patients), we were un-
able to perform an extensive array of other TB diagnostics tests 
such as imaging or sputum collection to corroborate the urine 
results. However, urine TB-LAM has a high specificity (≥98% 
in TB/HIV-coinfected patients), and although there is a lack of 
published data on the specificity of urine Ultra, Ultra has a high 
specificity when used on other clinical samples [11, 15]; there-
fore, in this study population with advanced HIV disease in a 
setting known to have a high prevalence of TB, we believe the 
risk of false-positive results is minimal. The duration of urine 
Xpert Ultra positivity after prior TB treatment is unknown, but 
given the continuous filtration of the kidneys and that urine 
is normally a sterile fluid, it is unlikely that nonviable bacilli 
would persist months or years after prior treatment, although 
further study of this point is warranted.
CONCLUSIONS
In conclusion, we have demonstrated a 26% prevalence of pos-
itive urine TB tests in patients presenting with HIV-associated 
meningitis. Our results support the expanded use of TB urine 
diagnostics in patients with meningitis to optimize timely diag-
nosis and treatment of TB, especially, but not only, in settings 
such as sub-Saharan Africa where TB infection prevalence is 
extremely high. Further studies are required to investigate 
whether disseminated TB is an independent risk factor for death 
in cryptococcal meningitis and whether enhanced TB treatment 
can improve outcomes. We have also shown that urine TB diag-
nostics are of use in TB meningitis; first as rapid, noninvasive 
adjunctive tests for suspected TB meningitis and second, pos-
sibly, as a prognostic tool in patients with HIV-associated TB 
meningitis. Further research is required to investigate the lack 
of concordance between urine TB-LAM and urine Xpert Ultra.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
Supplementary Table 1. Demographic, HIV, clinical, and laboratory fac-
tors by urine TB diagnostic result.
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